CD274 and neoplasm: PD-L1 antibodies like durvalumab or atezolizumab harbor IgG1 instead of IgG4, but these regions have been genetically engineered to significantly reduce CDC or ADCC potentially directed not only at the tumor cell but also at PD-L1-positive cells within the tumor microenvironment (8, 9).